	US 12,251,381 B2
	Aripiprazole dosing strategy
Lisa L. von Moltke, Newton, MA (US); Peter J. Weiden, Newton, MA (US); and Marjie L. Hard, Lexington, MA (US)
Assigned to Alkermes Pharma Ireland Limited, Dublin (IE)
Filed by Alkermes Pharma Ireland Limited, Dublin (IE)
Filed on Feb. 4, 2022, as Appl. No. 17/665,015.
Application 17/665,015 is a continuation of application No. 16/291,768, filed on Mar. 4, 2019, granted, now 11,273,158.
Claims priority of provisional application 62/638,587, filed on Mar. 5, 2018.
Prior Publication US 2022/0152021 A1, May 19, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/497 (2006.01); A61K 9/00 (2006.01); A61K 31/496 (2006.01); A61K 47/02 (2006.01); A61K 47/12 (2006.01); A61K 47/26 (2006.01); A61P 25/18 (2006.01)

CPC A61K 31/497 (2013.01) [A61K 31/496 (2013.01); A61K 47/02 (2013.01); A61K 47/12 (2013.01); A61K 47/26 (2013.01); A61P 25/18 (2018.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01)]

27 Claims

1. A method of treating schizophrenia in a subject in need thereof, the method comprising administering to the subject:

a first component comprising about 5-50 mg of aripiprazole;

a second component comprising about 629-695 mg of AL_NCDhaving a volume-based particle distribution size (Dv50) between about 175 nm and about 350 nm; and

a third component comprising a therapeutically effective amount of aripiprazole lauroxil;

wherein the method comprises a regimen wherein the first component is only administered on the first and/or second days of treatment, the second component is only administered on the first day of treatment, and the third component is only administered once within the first 10 days of treatment.